Fibnib 100mg Soft Gelatin Capsule contains Nintedanib, a potent tyrosine kinase inhibitor used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Nintedanib works by blocking multiple pathways involved in the proliferation and migration of fibroblasts and tumor cells, thereby slowing disease progression. Fibnib is indicated for patients diagnosed with IPF to reduce lung function decline and improve quality of life, as well as for use in combination with chemotherapy for advanced or metastatic NSCLC. The soft gelatin capsule formulation ensures ease of swallowing and optimal bioavailability. Patients are advised to take Fibnib with food to minimize gastrointestinal side effects such as nausea, diarrhea, and abdominal pain, which are the most commonly reported adverse reactions. Liver function tests should be monitored regularly during treatment due to potential hepatotoxicity. Fibnib is contraindicated in patients with known hypersensitivity to Nintedanib or any capsule components. Caution is advised in patients with bleeding risks or recent surgery. This medication should be used under strict medical supervision, with dosage adjustments based on tolerability and clinical response to maximize therapeutic benefits while minimizing risks.